Search | Clinical Trials Finder

Conditions: Venous Leg Ulcers
Interventions: HP802-247; Biological
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Allergic Conjunctivitis
Interventions: Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK0803, Excipient; Biological · Other
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 5
States / cities: Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more

Conditions: Submental Fat
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Atopic Dermatitis
Interventions: Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions: PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Artesia, California • Newport Beach, California • Petaluma, California + 15 more

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical Vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Dry Eye
Interventions: 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle); Drug
Lead sponsor: Yuyu Pharma, Inc.; Industry
Eligibility: Not listed
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 4 more

Conditions: Neurofibromatoses
Interventions: Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Allergic Conjunctivitis
Interventions: PRT-2761 0.5%, PRT-2761 1%, Patanol, Pred-forte, PRT-2761 0%; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Plaque Type Psorisis
Interventions: Tapinarof Cream 1%, VTAMA®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more

Conditions: Dry Eye
Interventions: VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle; Drug
Lead sponsor: VivaVision Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Solid Tumor
Interventions: Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 9
States / cities: Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more

Conditions: Healthy Volunteers
Interventions: [14C]-BGB-16673; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Post Surgical Ocular Inflammation and Pain
Interventions: KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 35
States / cities: Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more

Conditions: Hyperhidrosis
Interventions: Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle; Drug · Other
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Encinitas, California • Fremont, California • Tampa, Florida + 10 more

Conditions: Non-segmental Vitiligo
Interventions: VYN201 Gel, Vehicle Gel; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Pachyonychia Congenita
Interventions: 1% sirolimus cream (TD201 1%); Drug
Lead sponsor: TransDerm, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions: OTX-101 0.05%, OTX-101 0.09%, Vehicle; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca